CYTOMX THERAPEUTICS INC
CTMXNASDAQ🏆 #2221 by market capEarnings Nov 4US Equity
$437.81▼ $7.79 (−1.78%)
Simulated price1h—
24h▼ 1.8%
7d▲ 13008.1%
14d▲ 13689.3%
30d▲ 11748.7%
1y▲ 23187.8%
🏦Market Cap
$750M
Small Cap
📈Revenue Growth (YoY)
-75.9%
Declining
📊Gross Margin
—
💵FCF Margin
26.2%
Strong
⚖️P/S Ratio
20.8x
Expensive
Otter Score
51
Weak
Trading Snapshot
- Day Range
- $434.31 – $445.49
- 52-Week Range
- $1.72 – $8.21
- Volume
- $2.75B
- Avg Volume
- $2.24B
- Shares Outstanding
- 217.7M
- Next Earnings
- Oct 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $36M
- Last Q Revenue
- $9M
- P/E Ratio
- —
- P/S Ratio
- 20.8x
- EPS (TTM)
- $-0.35
- Dividend Yield
- —
Why Investors Own CTMX
- ✓High-growth profile — revenue up +42.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$36M▲ +43.5% YoY
Gross Margin (TTM)
65.4%▲ +4.5% YoY
Operating Income (TTM)
$8M▲ +43.5% YoY
Free Cash Flow (TTM)
$3M▲ +43.5% YoY
About CYTOMX THERAPEUTICS INC
A company profile for CYTOMX THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
51/100
Analyst Price Target
ⓘAverage Target
$521.84
▲ +19.2% Upside
High Target$587.39
Low Target$443.21
Based on 27 analysts
Latest News & Updates
🚀
Barron’s·2h ago
CYTOMX THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift CTMX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
CYTOMX THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.